- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05767684
Neoantigen Derived DCs as Cancer Treatment
August 23, 2023 updated by: National Health Research Institutes, Taiwan
Personalized Neoantigen Derived Dendritic Cell-Based Immunotherapy as Cancer Treatment
Tumor lysate or carcinoembryonic antigen (CEA) derived DCs-based therapy is safe and can elicites remarkable T-cell responses but mostly did not really transfer into significant clinical benefit.
One possible reason is the lack of effective antigen and the immunosuppressive microenvironment.
Now we are exploring another new strategy, prediction of neoantigen for priming DCs as cell-based therapy with or without booster of anti-VEGF/anti-PD-1.
Study Overview
Status
Recruiting
Conditions
Intervention / Treatment
Detailed Description
The human immune system can recognize and destroy cancer cells but cancer cells are capable of escaping from immune system by different ways, including the PD-1/PDL-1 axis and the VEGF signaling pathway.
The PD-1/PD-L1 axis represents an adaptive immune resistance mechanism exerted by tumor cells.
Previous study also revealed VEGF-A could induce tumor-associated macrophages, Treg cells, and myeloid-derived suppressor cells, creating an immunosuppressive microenvironment that prevent the maturation of dendritic cells (DCs) and inhibit the activation of NK cells and T cells.
Our research group already completed some early phase clinical trials of DCs-based therapy, which illustrated tumor lysate or carcinoembryonic antigen (CEA) derived DCs-based therapy is feasible and safe in patients with advanced colorectal cancer and lung cancer, respectively.
However, although DCs-based therapy elicited remarkable T-cell responses but mostly did not really transfer into significant clinical benefit in previous study.
One possible reason is the lack of effective antigen and the immunosuppressive microenvironment.
Now we are exploring another new strategy, prediction of neoantigen for priming DCs as cell-based therapy with or without booster of anti-VEGF/anti-PD-1.
Study Type
Interventional
Enrollment (Estimated)
12
Phase
- Phase 1
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Contact
- Name: Kuan-Chung Hsiao, PhD
- Phone Number: 65108 +886-6-7000123
- Email: randolph.hsiao@gmail.com
Study Contact Backup
- Name: Yung-Yeh Su, MD
- Phone Number: 65181 +886-6-7000123
- Email: yysu@nhri.edu.tw
Study Locations
-
-
-
Kaohsiung, Taiwan
- Not yet recruiting
- Kaohsiung Medical University Hospital
-
Contact:
- Li-Tzong Chen, MD, PhD
- Email: leochen@nhri.edu.tw
-
Tainan, Taiwan
- Recruiting
- National Cheng-Kung University Hospital
-
Contact:
- Yung-Yeh Su, MD
- Phone Number: 65181 +886-6-7000123
- Email: yysu@nhri.edu.tw
-
Tainan, Taiwan
- Recruiting
- National Institute of Cancer Research
-
Contact:
- Yung-Yeh Su, MD
- Phone Number: 65181 +8867-7000123
- Email: yysu@nhri.edu.tw
-
Principal Investigator:
- Li-Tzong Chen, MD, PhD
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
20 years and older (Adult, Older Adult)
Accepts Healthy Volunteers
No
Description
Inclusion Criteria:
- ≥20 years of age
- Provide written informed consent
- Histologically confirmed stage IV pancreatic cancer, liver cancer, biliary tract cancer and colorectal cancer (excluding sarcoma and neuroendocrine tumor) that refractory or intolerance to standard therapies for their condition (there is no effective treatment by investigator judgement)
- Completed tumor and germline DNA and RNA sequencing and the neoantigen prediction
- Patients with chronic hepatitis B is eligible if receiving anti-hepatitis B agents and the HBV DNA level < 2000 IU/ml prior to the preparation phase. Patients with chronic hepatitis C are eligible if HCV RNA is undetectable (<15 IU/ml) prior to the preparation phase
Adequate organ function
- Absolute neutrophil count >1000/mcL
- Hemoglobin > 8.0 g/dl
- Platelet > 50000/mcL
- PT/aPTT < 1.5 x upper limit of normal (ULN)
- AST/ALT < 3 x ULN
- Bil(T) < 1.5 x ULN
- BUN/Cr < 1.5 x ULN
Adequate immune system as defined by
- IgG > 614 mg/dl
- IgM > 53mg/dl
- Eastern Cooperative Oncology Group (ECOG) performance status 0, 1, or 2
- Life expectancy at least>12weeks
- At least one measurable target lesion as defined by RECIST 1.1
Exclusion Criteria:
- Sarcoma、neuroendocrine tumor
- Last anticancer therapy administered within 2 weeks and any AEs should be ≤ grade 2 prior to leukapheresis
- Patients who cannot tolerate leukapheresis and follow-up blood sampling of 50ml at day 43, day 85 and end-of- treatment.
- Any known active infection as judged by the investigator
- Any known chronic active infection of HIV, HTLV-1 or HTLV-2
- Requirement of systemic treatment with either corticosteroids (> 10 mg daily prednisone equivalents) or other immunosuppressive medications within 14 days prior to the screen phase. Inhaled or topical steroids and adrenal replacement doses > 10 mg daily prednisone equivalents are permitted in the absence of active autoimmune disease.
- Other immunocompromising condition that in the opinion of the treating physician renders the patient a poor candidate for this trial
- Pregnant women, nursing women, men or women of childbearing potential who are unwilling to employ adequate contraception (condoms, diaphragm, birth control pills, injections, intrauterine device (IUD), abstinence, etc.)
- Patients with history of penicillin allergy
- Other medical problems or conditions that, in the opinion of the investigator, would make participation in the study hazardous for the patient
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Arm 1: DCs monotherapy
DCs injection on day 1, 8, 15, 29, 85, 141, 197, 253 and 309.
|
Approximately 1.5 x 10^6±20% cells will be subcutaneously injected to the patient's inguinal area (either left side or right side can be injected, only one area will be injected each time) on day 1, 8, 15, 29, 85, 141, 197, 253 and 309.
Other Names:
|
Experimental: Arm 2: DCs with booster of anti-VEGF/anti-PD-1.
DCs injection on day 1, 8, 15, 29, 85, 141, 197, 253 and 309 plus lenvatinib 10mg QD on day 43-77 and nivolumab 3mg/kg on day 43, 57 and 71.
|
Approximately 1.5 x 10^6±20% cells will be subcutaneously injected to the patient's inguinal area (either left side or right side can be injected, only one area will be injected each time) on day 1, 8, 15, 29, 85, 141, 197, 253 and 309.
Other Names:
Lenvatinib 10mg/day on day 43-77
Other Names:
Nivolumab 3mg/kg on day 43, 57 and 71.
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Number of subjects experienced limiting toxicities in the first 6 weeks.
Time Frame: 6 weeks
|
The following toxicities that happened during first 6 weeks are considered LTs. Toxicities are graded using Common Terminology Criteria for Adverse Events (CTCAE) version 5.0:
|
6 weeks
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Percentage of patients who had a clinical response
Time Frame: 1 year
|
Response was assessed by the iRECIST.
|
1 year
|
Number of participants who did not progressed or survived at 1 year
Time Frame: 1 year
|
1 year progression-free survival and overall survival rate
|
1 year
|
Number of subjects experienced any ≥ grade 3 toxicities.
Time Frame: 1 year
|
any ≥ grade 3 toxicities rate
|
1 year
|
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Number of subjects experienced immune response
Time Frame: 1 year
|
The production of IFN-γ that occurs subsequent to the dendritic cells-based therapy as determined by ELISPOT Assay or Flow Cytometry Analysis.
Other immune response biomarker study including but not limited to whole exome sequencing, bulk RNA sequencing and single cell RNA sequencing.
|
1 year
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Collaborators
Investigators
- Principal Investigator: Li-Tzong Chen, MD, PhD, Kaohsiung Medical University Hospital, and Center for Cancer Research, Kaohsiung Medical University
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
June 1, 2023
Primary Completion (Estimated)
March 30, 2025
Study Completion (Estimated)
March 30, 2026
Study Registration Dates
First Submitted
March 2, 2023
First Submitted That Met QC Criteria
March 2, 2023
First Posted (Actual)
March 14, 2023
Study Record Updates
Last Update Posted (Actual)
August 25, 2023
Last Update Submitted That Met QC Criteria
August 23, 2023
Last Verified
February 1, 2023
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- A-BR-108-087
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
NO
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Solid Tumor
-
Memorial Sloan Kettering Cancer CenterRecruitingSolid Tumor | Solid Tumor, Adult | Solid Tumor, Unspecified, AdultUnited States
-
Memorial Sloan Kettering Cancer CenterLincoln Medical and Mental Health CenterRecruitingSolid Tumor | Solid Tumor, Adult | Solid Tumor, Unspecified, AdultUnited States, Puerto Rico
-
Memorial Sloan Kettering Cancer CenterLincoln Medical and Mental Health CenterRecruitingSolid Tumor | Solid Tumor, Adult | Solid Tumor, Unspecified, AdultUnited States, Puerto Rico
-
Sorrento Therapeutics, Inc.WithdrawnSolid Tumor | Relapsed Solid Tumor | Refractory Tumor
-
RemeGen Co., Ltd.CompletedMetastatic Solid Tumor | Locally Advanced Solid Tumor | Unresectable Solid TumorAustralia
-
Aadi Bioscience, Inc.RecruitingAdvanced Solid Tumor | Tumor | Tumor, SolidUnited States
-
Impact Therapeutics, Inc.RecruitingSolid Tumor | Advanced Solid TumorChina, Taiwan, United States, Australia
-
Partner Therapeutics, Inc.WithdrawnSolid Tumor | Solid Tumor, AdultUnited States
-
Jazz PharmaceuticalsMerck Sharp & Dohme LLCRecruitingAdvanced Solid Tumor | Metastatic Solid TumorUnited States
-
PharmaEngineNot yet recruitingAdvanced Solid Tumor | Metastatic Solid Tumor
Clinical Trials on Dendritic Cell Vaccine
-
Hospital Clinic of BarcelonaCompleted
-
Jan WalewskiCompletedLymphoma | Multiple Myeloma and Plasma Cell NeoplasmPoland
-
H. Lee Moffitt Cancer Center and Research InstituteUnited States Department of DefenseRecruitingTriple Negative Breast Cancer | HER2-positive Breast Cancer | Leptomeningeal DiseaseUnited States
-
Oslo University HospitalActive, not recruiting
-
University of Maryland, BaltimoreWithdrawnSquamous Cell Carcinoma of Head and NeckUnited States
-
Memorial Sloan Kettering Cancer CenterNational Cancer Institute (NCI); National Institutes of Health (NIH); Rockefeller...CompletedMelanomaUnited States
-
University of PittsburghCompletedSezary Syndrome | Cutaneous T-cell LymphomaUnited States
-
Radboud University Medical CenterDutch Cancer SocietyCompletedMelanoma Stage III or IVNetherlands
-
Cedars-Sinai Medical CenterCompletedGlioblastomaUnited States
-
Fundacion Clinic per a la Recerca BiomédicaCompletedColorectal NeoplasmsSpain